Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001193125-24-036373
Filing Date
2024-02-14
Accepted
2024-02-14 16:36:53
Documents
1
Group Members
FLAGSHIP PIONEERING SPECIAL OPPORTUNITIES FUND II GENERAL PARTNER LLCFLAGSHIP PIONEERING SPECIAL OPPORTUNITIES FUND II, L.P.FLAGSHIP PIONEERING, INC.FLAGSHIP VENTURES FUND V GENERAL PARTNER LLCNOUBAR B. AFEYAN, PH.D.

Document Format Files

Seq Description Document Type Size
1 SC 13G/A d783133dsc13ga.htm SC 13G/A 107124
  Complete submission text file 0001193125-24-036373.txt   109005
Mailing Address ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Business Address ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142 617-868-1888
Flagship Ventures Fund V, L.P. (Filed by) CIK: 0001627639 (see all company filings)

EIN.: 611749444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Subject) CIK: 0001821323 (see all company filings)

EIN.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-92195 | Film No.: 24639371
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)